drugset / Trial / NCT02401048
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
Phase 1/2
Completed
61 enrolled
Pharmacyclics LLC.
AstraZeneca · collabJanssen Research & Development, LLC · collab
Non-randomizedFactorialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in subjects with relapsed or refractory lymphomas.
Timeline
- Start
- 2015-05
- Primary completion
- 2017-11
- Completion
- 2017-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Ibrutinib | Small molecule | 560 mg | — |